Schonfeld Strategic Advisors LLC bought a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 80,000 shares of the company's stock, valued at approximately $1,762,000.
Other hedge funds have also made changes to their positions in the company. Juncture Wealth Strategies LLC increased its position in Cellebrite DI by 0.8% in the fourth quarter. Juncture Wealth Strategies LLC now owns 60,003 shares of the company's stock worth $1,322,000 after buying an additional 505 shares during the period. TD Waterhouse Canada Inc. grew its position in shares of Cellebrite DI by 1.8% during the fourth quarter. TD Waterhouse Canada Inc. now owns 47,497 shares of the company's stock worth $1,046,000 after acquiring an additional 859 shares during the last quarter. Strategic Advisors LLC increased its holdings in shares of Cellebrite DI by 3.4% in the 4th quarter. Strategic Advisors LLC now owns 29,082 shares of the company's stock worth $641,000 after acquiring an additional 950 shares during the period. Steward Partners Investment Advisory LLC lifted its position in Cellebrite DI by 12.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 13,590 shares of the company's stock valued at $299,000 after purchasing an additional 1,463 shares during the last quarter. Finally, Tower View Wealth Management LLC grew its position in Cellebrite DI by 1.3% in the 4th quarter. Tower View Wealth Management LLC now owns 132,307 shares of the company's stock worth $2,915,000 after purchasing an additional 1,660 shares during the last quarter. Institutional investors own 45.88% of the company's stock.
Cellebrite DI Stock Performance
Cellebrite DI stock opened at $19.71 on Tuesday. Cellebrite DI Ltd. has a 1 year low of $10.25 and a 1 year high of $26.30. The firm's 50 day moving average price is $18.84 and its two-hundred day moving average price is $20.22. The firm has a market cap of $4.72 billion, a price-to-earnings ratio of -14.18, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, equities analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on CLBT shares. JPMorgan Chase & Co. boosted their price objective on Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. Lake Street Capital increased their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a report on Friday, February 14th. Finally, Needham & Company LLC reissued a "buy" rating and set a $28.00 target price on shares of Cellebrite DI in a report on Wednesday, April 2nd. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Cellebrite DI has an average rating of "Buy" and an average price target of $23.43.
Get Our Latest Stock Analysis on Cellebrite DI
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Read More
Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
